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Abstract Clinical studies in chronic myelogenous leukemia
demonstrate that the overexpression of Bcr-Abl tyrosine kinase
is usually accompanied by relatively low telomerase activity in
the chronic phase, which reverts to a high activity in blast crisis.
The present study was designed to investigate the cross-talk
between both enzymes, using Bcr-Abl-positive K-562 and Bcr-
Abl-negative Jurkat cell lines, treated with antisense oligode-
oxyribonucleotides (ODNs) against Bcr-Abl/c-Abl mRNA.
The decreased amount and enzyme activity of Bcr-Abl/c-Abl
provoked telomerase activation in both cell lines. After short-
term treatment with anti-Bcr-Abl/c-Abl ODNs (6 days), no var-
iations in hTERT and phospho-hTERT were detected. The de-
creased amount of Bcr-Abl/c-Abl was accompanied by: altera-
tions in telomeric associated proteins^overexpression of
tankyrase and decreased amount of TRF1/Tin2, cell growth
arrest of K-562 cells, reaching a plateau after 6 days treatment,
and increased proliferating activity of Jurkat cells. No changes
in telomere length were detected after short-term treatment. In
contrast, after long-term treatment with anti-Bcr-Abl/c-Abl
ODNs (36 days), a signi¢cant elongation of telomeres and en-
hancement of hTERT were established, accompanied by an in-
creased proliferating activity of both cell lines. These data pro-
vide evidence that the inhibition of Bcr-Abl or c-Abl synthesis
keeps a potential to restore or induce cell proliferation through
telomere lengthening control and telomerase activation.
4 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The Bcr-Abl oncogene is a result of a reciprocal transloca-
tion between the long arms of chromosomes 9 and 22 (known
as Philadelphia (Ph) chromosome; t(9;22)), encoding a cyto-
plasmic protein with constitutive tyrosine kinase activity that
inhibits apoptosis. There is good experimental evidence dem-
onstrating that Bcr-Abl is a single causative abnormality in
chronic myelogenous leukemia (CML), at least in the chronic
phase, making it a unique model for the development of mo-
lecular targets for disease control [1^3]. The increased knowl-
edge of Bcr-Abl has resulted in the design of several novel
therapeutic approaches, including highly speci¢c tyrosine ki-
nase inhibitors (such as Glivec and pyrido[2,3-d]pyrimidine
derivative PD180970), antisense strategies and immunomodu-
lation [1^4].
The chronic phase of CML is also unique, in comparison
with other types of leukemia, with its relatively low telomerase
activity [5]. Approximately 80% of CML patients in the
chronic phase show reduced telomere length and low telomer-
ase activity, in contrast to a large number of tumors and
immortalized cell lines in which telomerase is overexpressed
[5^7]. However, during CML progression to the acute phase,
termed blast crisis, more than 60% (up to 80%) of patients
show additional cytogenetic changes, resulting in genome in-
stability, enhanced telomerase activity and telomere dynamics
[5,7]. It has been observed that the telomerase activity has a
high prognostic impact for CML and its enhancement is as-
sociated with shorter survival of the patients. It seems that
both abnormalities responsible for immortalization of Ph(+)
leukemia cells ^ Bcr-Abl tyrosine kinase and telomerase ^ are
essential in equal degrees for the exit of the disease. With the
advent of new anti-CML drugs, it is important to clarify
whether cross-talk exists between both key enzymes, how
the drugs in£uence this relationship, how this plays a func-
tional role in CML progression and at relapse with the devel-
opment of chemotherapy resistance.
The catalytic core of human telomerase consists of an RNA
template, a catalytic protein subunit with reverse transcriptase
activity (hTERT) and additional telomerase-associated pro-
teins [8,9]. hTERT is considered a phosphoprotein. Its revers-
ible phosphorylation by a complex set of protein kinases
seems to be a prerequisite for modulation of telomerase ac-
tivity and its connection with signal transduction pathways
[10^12]. Two antagonistic protein kinase-dependent mecha-
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and X16416, respectively. ODN1/PS-ODN1 antisense sequences and
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nucleotide sites localized in the breakpoint cluster region (b3a2
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sequences and ODN4/PS-ODN4 control sense sequences correspond
to the nucleotide site of Abl proto-oncogene, localized between ex.
961 and 1021 (accession number X16416, version X16416.1). ODN5
and PS-ODN5 are nonsense sequences and did not show homology
with both cDNAs.
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nisms for telomerase regulation have been described: (1) pro-
tein kinase C/B-dependent activation [10,11], and (2) c-Abl-
dependent inhibition of the enzyme [12].
Proceeding from the fact that Bcr-Abl fusion strongly acti-
vates Abl tyrosine kinase and therefore potentiates telomerase
suppression in Ph(+) cells, it is possible to explain, at least
partially, the relatively low telomerase activity in the chronic
phase of CML. It has been established that other chromosom-
al translocations that generate fusion proteins (for example
Tel-Abl) are also characterized by enhanced Abl-tyrosine ki-
nase activity and low telomerase activity [7]. A ‘vicious circle’
seems to take place in Ph(+) cells and selective c-Abl inhib-
itors would have a potential to restore cell immortalization
through telomerase activation.
On the other hand, recently it has been reported that pro-
tein kinase (PK) CS activity is necessary for Bcr-Abl-mediated
resistance to drug-induced apoptosis [13]. Inhibition of Bcr-
Abl using the highly selective inhibitor tyrphostin AG957
completely abolishes PKCS activation and sensitizes (Ph+)
K-562 cells to drug-induced apoptosis. Therefore, the selective
Bcr-Abl inhibitors also possess a potential to suppress telo-
merase indirectly through the inhibition of atypical PKC iso-
enzymes.
Obviously, there is a ¢ne link between Bcr-Abl tyrosine
kinase and telomerase in CML and the e⁄cacy of drug ther-
apy depends on this relationship. During disease progression
chemotherapy can restore or avoid the immortalization of
Ph(+) cells through direct or indirect (PK-mediated) telomer-
ase control, regardless of its strong and selective inhibitory
e¡ect on Bcr-Abl. A good understanding of the cross-talk
between telomerase and Bcr-Abl tyrosine kinase is potentially
useful for development of a new strategy for CML control
and for decrease of resistance to the drug-target therapy.
The present study was designed to investigate this relation-
ship, using (Ph+) K-562 cells, treated with antisense oligo-
deoxyribonucleotides (ODNs) against mRNA for fusion pro-
tein and the ATP-binding loop of the Bcr-Abl molecule. As a
negative control Ph-negative (Ph3) Jurkat cells were tested.
2. Materials and methods
2.1. ODNs
The sense mRNA/cDNA sites and antisense sequences are shown in
Fig. 1A. Two types of ODNs were used: phosphorothioate-derivat-
ized (PS-ODN1 and PS-ODN2) and non-derivatized (ODN1 and
ODN2, termed ‘native’). The following non-derivatized and PS-deriv-
atized sense and nonsense sequences were used as negative controls:
ODN3 (Bcr-Abl sense), 3P-S-CCCTCTTCGAAGACTTTGTGAAG-
5P ; ODN4 (c-Abl sense), 3P-S-AAAGTACTGACGTCGAAGAAAG-
5P ; ODN5 (nonsense), 3P-S-AAGTTTGTCGTTAAAGGACAG-5P.
2.2. Cells and transfection protocol
K-562 (derived from CML patients in blast crisis) and Jurkat cells
(derived from patients with acute lymphoblastic leukemia, ALL) were
a generous gift of Dr. J. Minowada (Hayashibara Biochemical Labo-
ratories, Okayama, Japan). The cells were cultured in RPMI 1640
medium, supplemented with 10% heat-inactivated fetal bovine serum
in a humidi¢ed atmosphere at 37‡C with 5% CO2. The cells used for
transfection were about 80% con£uent.
Transfection conditions: collection of cells by centrifugation, resus-
pension of cells in a new medium to 8U105 cells/ml, ODN (5 WM)
transfection using lipofectamine (6 h), replacement of cells in a new
medium (4U105 cells/ml) and cultivation in a humidi¢ed atmosphere.
The conditions for preparation of ODN^lipofectamine complexes are
described in the Lipofectamine ’2000 protocol (Invitrogen).
2.3. Fluorescent confocal microscopy ^ ODN delivery into the cells
Cells (2U105/ml) were cultured for 24 h in the presence of £uores-
cein isothiocyanate (FITC)-labeled PS-ODN1 or FITC-PS-ODN2
(single dose 1 WM), or transfected with FITC-labeled ODNs (single
dose 1 WM) using lipofectamine as described above. Six hours tran-
sient transfection was applied and transfected cells were cultured in
RPMI 1640 medium. At 24 h post transfection (in the case of ODNs)
or 24 h incubation (in the case of PS-ODNs) the cells were sedimented
by centrifugation (1000Ug/10 min), washed twice with phosphate-
bu¡ered saline (PBS) (Ca2þ- and Mg2þ-free) to eliminate free £uores-
cent PS-ODN molecules outside the cells, and the FITC-labeled PS-
ODNs, incorporated into living cells (green spots), were detected by
£uorescent confocal microscopy. The samples were analyzed with an
Olympus IX70 microscope.
2.4. Telomerase activity assay
Telomerase activity was detected by a conventional telomeric repeat
ampli¢cation protocol (TRAP) and the Stretch polymerase chain re-
action (PCR) method, using the Telomerase assay kit (TeloChaser,
Toyobo), with slight modi¢cations. Brie£y, the cells (2U104) were
lysed in 25 Wl TeloChaser bu¡er (containing protease and phosphatase
inhibitor cocktail, Toyobo) for 30 min, at 4‡C. The sample was cen-
trifuged at 12 000Ug/20 min, at 4‡C. The supernatant was used in the
next procedure. Telomerase activity was assayed by a two-step pro-
cess: (i) telomerase-mediated extension (20 min, 30‡C) of an oligonu-
cleotide (TAG-U primer, containing telomeric repeats), and (ii) PCR
ampli¢cation of the resulting product using forward and reverse prim-
ers [14]. The PCR reaction consisted of 32 cycles (30 s at 95‡C, 30 s at
68‡C, and 45 s at 72‡C). GeneAmp PCR System 9700 (Applied Bio-
systems) was used. The product of telomerase reaction was analyzed
by TBA electrophoresis in a non-denaturing 12% polyacrylamide gel.
Gels were stained with Silver Staining kit (Pharmacia Biotech), ac-
cording to the manufacturer’s instruction. As a negative control, an
aliquot of each sample was incubated at 70‡C for 10 min to inactivate
telomerase.
2.5. Immunoblot analyses
2.5.1. Bcr-Abl/c-Abl detection. The cells were treated with anti-
sense ODNs as shown in Fig. 1D. Aliquots of 4U105 cells were lysed
in TeloChaser bu¡er (containing protease and phosphatase inhibitor
cocktail) for 30 min at 4‡C, centrifuged at 12 000Ug/20 min/4‡C and
supernatant was dissolved 1:1 in 2ULaemmli sample bu¡er (1.1 M
Tris^HCl, pH 6.0, 3.3% sodium dodecyl sulfate (SDS), 22% glycerol,
10% L-mercaptoethanol, 0.001% bromophenol blue). Samples (with
6
Fig. 1. A: Sequences of chemically synthesized antisense ODNs against Bcr-Abl/c-Abl mRNA. B: Penetration of phosphorothioate (PS)-derivat-
ized ODNs (green spots) into living Ph(+) K-562 and Ph(3) Jurkat cells. Cells (2U105/ml) were cultured for 24 h in the presence of FITC-la-
beled PS-ODNs as described in Section 2. The cells were sedimented by centrifugation, washed twice with PBS (Ca2þ- and Mg2þ-free), and
FITC-labeled antisense substances, incorporated into living cells (green spots), were detected by £uorescent confocal microscopy. Quadrant a:
£uorescence; quadrant b: transmission; quadrant c: £uorescence and transmission. In the case of native ODNs (ODN1 and ODN2), no £uo-
rescence was detected in living K-562 and Jurkat cells (data not shown). C: Penetration of ODNs into living Ph(+) K-562 and Ph(3) Jurkat
cells after transient transfection with lipofectamine. Cells (2U105/ml) were transfected during 6 h with FITC-labeled ODNs using lipofectamine
and the procedure described in Section 2. At 24 h post transfection, the cells were sedimented by centrifugation, washed twice with PBS (Ca2þ-
and Mg2þ-free), and FITC-labeled antisense substances, incorporated into living cells (green spots), were detected by £uorescent confocal mi-
croscopy. Quadrant a: £uorescence; quadrant b: transmission; quadrant c: £uorescence and transmission. In the case of PS-ODNs, the data
were analogous to these in B. D: Scheme of ‘chronic’ treatment of K-562 and Jurkat cells by antisense ODNs. *New transfection conditions:
collection of cells by centrifugation, resuspension of cells in a new medium to 2U105 cells/ml, ODN (5 WM) transfection using lipofectamine
(6 h), replacement of cells in a new medium and cultivation in a humidi¢ed atmosphere.
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equal protein concentrations) were heated at 95‡C for 10 min and
were applied to 5% stacking, 4^12% resolving SDS^polyacrylamide
gel. Electrophoresis was carried out in two steps: at 80 V for 15
min, 120 V for 2 h at room temperature (RT, V22‡C). Bio-Rad
Kaleidoskop protein standards were also applied for comparison.
After electrophoresis the separated protein fractions were transferred
to a Hybond-P polyvinylidene di£uoride (PVDF) membrane (Amer-
sham Bioscience) using the XCell II Blot Module (Novex). The trans-
fer was carried out at 35 V for 18 h at 4‡C. The membranes were cut
at 45 kDa (for L-actin) and 150^210 kDa (for c-Abl and Bcr-Abl)
molecular weight levels. A double antibody procedure was used to
detect the proteins. The membranes were incubated under agitation
for 1 h at RT in a blocking solution (PBS, containing 5% dry
skimmed milk and 0.1% Tween-20), then at RT for 1 h in anti-c-
Abl (rabbit, Sigma; 1:100 dilution for Bcr-Abl and 1:500 for c-Abl
detection) or anti-L-actin monoclonal antibodies (mouse, Calbiochem;
1:20 000). The antibody solution was removed and the membranes
were washed three times with PBS containing 0.1% Tween-20. The
membranes were then incubated (1 h at RT under agitation) with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Sig-
ma, 1:5000) ^ for anti-c-Abl, and goat anti-mouse IgM (Sigma,
1:2000) ^ for anti-L-actin antibody. Chemiluminescence was detected
immediately using the ECL Advance Western Blotting Detection kit
(Amersham Bioscience).
2.5.2. hTERT (127 kDa) detection. The cells were lysed in Telo-
Chaser bu¡er and applied to SDS electrophoresis and immunoblot-
ting procedures, as described above. Anti-hTERT (rabbit, Calbio-
chem, 1:1000 diluted) was used as a primary antibody.
An immunoprecipitation procedure was applied before immuno-
blotting to register phospho-Tyr-hTERT (P-hTERT). hTERT was
immunoprecipitated from cell lysates using 0.4 Wg/ml anti-hTERT
antibody (rabbit, Calbiochem), according to the method of Li et al.
[15]. Antigen^antibody complexes were collected on protein G beads,
washed twice with TeloChaser bu¡er, and suspended 1:1 in
2ULaemmli bu¡er. Samples were fractionated by 5% stacking, 8%
resolving SDS^polyacrylamide gel. Proteins were transferred to a Hy-
bond-P PVDF membrane and immunoblotted (no dry skimmed milk
was used in a blocking procedure), using anti-hTERT antibody (rab-
bit, Calbiochem, 1:1000) as a primary antibody, and anti-rabbit HRP-
conjugated anti-phospho-Tyr antibody as a secondary one (Chemi-
con, 1:1500).
2.5.3. TRF1 (V56 kDa), Tin2 (V40 kDa) and tankyrase (V142
kDa) detection. The cells were lysed in TNE bu¡er (10 mM Tris, pH
7.8, 1% Nonidet P-40, 0.15 M NaCl, 1 mM EDTA, protease inhibitor
cocktail from Sigma) for 1 h at 4‡C. After centrifugation at 14 000Ug
for 10 min, the supernatant was treated with rabbit IgG and protein
G-Sepharose on ice for 20 min. Non-speci¢c antibody complexes
and protein aggregates were removed by centrifugation, and the super-
natant was used for immunoblot analysis. Endogenous L-actin was
used as an internal standard. The supernatant was added to 2U
Laemmli bu¡er (1:1, v:v). Samples were fractionated by 5% stacking,
4^20% resolving SDS^polyacrylamide gel. Proteins were transferred to
a Hybond-P PVDF membrane and immunoblotted. The following
primary antibodies were used: anti-tankyrase (rabbit, Calbiochem,
0.1 Wg/ml), anti-TRF1 (rabbit, Calbiochem, 0.7 Wg/ml), anti-Tin2
(mouse, Calbiochem, 0.5 Wg/ml), anti-L-actin (mouse, Sigma). The
respective secondary antibodies (goat anti-rabbit or anti-mouse
IgG), conjugated with HRP, were applied. Chemiluminescence of
the blots was detected immediately using ECL Advance Western Blot-
ting Detection kit.
2.6. Flow cytometry
Anti-c-Abl antibody (rabbit, Sigma) was labeled by ZenonAlexa
Fluor-488 Rabbit IgG Labeling kit (Molecular Probes). Permeabiliza-
tion of cells for Fluor-488-conjugated anti-c-Abl antibody was carried
out with IntraPrep Permeabilization Reagent (Immunotech). The anti-
body^antigen interaction was detected by £ow cytometry (Beckman
Coulter-Epics XL). Data were collected and analyzed with XL System
II software. No cells were excluded from the analysis andV5000 cells
were counted. Data are presented as a dot plot of Fluor-488 £uores-
cence (side scatter, y-axis in 0^128 scale, vs. Fluor-488-conjugated
antibody, x-axis in 31^1000 scale) with quadrant markers drawn to
distinguish the cells containing di¡erent levels of antibody^antigen
complexes.
C
Fig. 2. A: E¡ect of anti-Bcr-Abl/c-Abl ODNs on the levels of Bcr-Abl (210 kDa) and c-Abl (150 kDa) proteins in Ph(+) K-562 and Ph(3) Jur-
kat cells, respectively ^ Western blot analysis. The cells were treated with antisense ODNs as shown in Fig. 1D. Cell lysates were obtained after
2, 4 and 6 days treatment as described in Section 2. The samples (at equal protein concentrations) were dissolved 1:1 in 2ULaemmli bu¡er,
heated at 95‡C for 10 min and subjected to SDS^polyacrylamide gel electrophoresis (80 V, 15 min; 120 V, 2 h at RT). The separated protein
fractions were transferred to a Hybond-P PVDF membrane overnight at 35 V (4‡C). The membranes were cut at 45 kDa (for L-actin) and
150^210 kDa (for c-Abl/Bcr-Abl) and were incubated as follows: 1 h at RT in a blocking solution, 1 h in anti-c-Abl antibody (rabbit, Sigma,
1:100 for detection of Bcr-Abl and 1:500 for detection of c-Abl) or in anti-L-actin antibody (mouse, Calbiochem, 1:20 000), 1 h with HRP-con-
jugated goat anti-rabbit IgG (Sigma, 1:5000) for anti-c-Abl or goat anti-mouse IgM (Sigma, 1:2000) for anti-L-actin. Chemiluminescence was
detected immediately using ECL Advance Western Blotting Detection kit. Blots from one typical experiment for each protein are shown in the
¢gure. Control blots are representative for non-treated cells, cells treated with lipofectamine only, and for cells transfected with sense or non-
sense ODNs/PS-ODNs. B: E¡ect of anti-Bcr-Abl/c-Abl ODNs (6 days treatment) on the level of Bcr-Abl and c-Abl proteins in Ph(+) K-562
and Ph(3) Jurkat cells, respectively ^ £ow cytometric analysis. The cells were treated with antisense ODNs during 6 days as shown in Fig. 1D.
Anti-c-Abl (rabbit, Sigma) was labeled by ZenonAlexa Fluor-488 Rabbit IgG Labeling kit. Permeabilization of cells for Fluor-488-conjugated
anti-c-Abl was carried out by IntraPrep permeabilization reagent (Immunotech). The antibody^antigen interaction was detected by £ow cytome-
try as described in Section 2. Data are presented as a dot plot of Fluor-488 £uorescence (side scatter, SS ^ y-axis in 0^128 scale, vs. Fluor-488-
conjugated antibody, Fluor-488 ^ x-axis in 31^1000 scale) with quadrant markers drawn to distinguish the cells containing di¡erent levels of
antibody^antigen complexes. In the histograms, quadrant H corresponds to the cells containing the maximum level of c-Abl/Bcr-Abl (positive
control), quadrant G corresponds to the cells without £uorescent marker and therefore without c-Abl/Bcr-Abl^antibody complexes (spontane-
ous cell £uorescence, negative control), and quadrant E (between H and G) corresponds to the cells containing a moderate or low level of Flu-
or-488-conjugated c-Abl antibody and therefore expressing moderate or lower levels of c-Abl/Bcr-Abl protein in comparison with the positive
control. To the right of each histogram Fluor-488 £uorescent curves are drawn. Histograms from one typical experiment are shown in the ¢g-
ure. Positive controls are representative for cells treated with lipofectamine only, and for cells transfected with sense or nonsense ODNs/PS-
ODNs. C: E¡ects of anti-Bcr-Abl/c-Abl ODNs (6 days treatment) on the tyrosine kinase activity in Ph(+) K-562 and Ph(3) Jurkat cells. The
cells were treated with antisense ODNs during 6 days as shown in Fig. 1D. Bcr-Abl and/or c-Abl were isolated from cell lysates by immunopre-
cipitation, using anti-c-Abl antibody (Sigma, 3 Wg/ml) and protein A/G agarose beads. The tyrosine kinase activity of immunoprecipitated en-
zymes (C1) as well as of cell lysates (C2) was analyzed spectrophotometrically, using Chemicon’s PTK Assay kit. The fraction of phosphorylat-
ed substrate was visualized at 450 nm, using HRP-conjugated anti-phosphotyrosine antibody (clone PY20) and ensuing chromogenic substrate
reaction. The data are presented as meansWS.D. from eight independent experiments. They were calculated as a percentage of control tyrosine
kinase activity, analyzed in non-treated cells. The values of PTK activity in control groups (C1, C2) were considered as 100%. In non-treated
cells, the absolute values of P-Tyr-peptide substrate (accumulated for 60 min at 37‡C in the presence of immunoprecipitated PTK) were
12.60W1.25 and 17.48W 1.67 ng for Jurkat and K-562 respectively. In the case of cell lysates, the absolute values of P-Tyr-peptide substrate ob-
tained from non-treated Jurkat or K-564 cells were 11.22W 1.15 and 14.65W 1.07 ng, respectively. OD450nm = 1.0 corresponds to 20 ng P-Tyr-
peptide substrate. The calibration curve was linear in the range 10^40 ng P-Tyr-peptide substrate. Control groups are representative for non-
treated cells, cells treated with lipofectamine only, and for cells transfected with sense or nonsense ODNs/PS-ODNs. þP6 0.05 vs. C1,
þþP6 0.01 vs. C1, þþþP6 0.001 vs. C1; *P6 0.05 vs. C2, **P6 0.01 vs. C2, ***P6 0.001 vs. C2.
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2.7. Tyrosine kinase activity test
The cells were sedimented by centrifugation (1000Ug/10 min),
washed twice with PBS (Ca2þ- and Mg2þ-free) and resuspended in
lysis bu¡er (TeloChaser). Lysis was carried out for 30 min at 4‡C.
The cytosolic fraction, containing Bcr-Abl and/or c-Abl, was obtained
after centrifugation at 12 000Ug/10 min, 4‡C. Bcr-Abl and/or c-Abl
proteins were isolated by immunoprecipitation, using anti-c-Abl anti-
body (Sigma, 3 Wg/ml) and protein A/G agarose beads. The tyrosine
kinase activity of immunoprecipitated enzyme as well as of cell lysates
was analyzed spectrophotometrically, using Chemicon’s protein tyro-
sine kinase (PTK) assay kit. Brie£y, a synthetic biotinylated poly-
[Glu:Tyr], 4:1 (2.5 Wg/ml), containing multiple tyrosine residues,
was used as a PTK substrate. The PTK reaction was started by
1 mM ATP/10 mM MgCl2 and continued for 60 min at 37‡C. The
enzyme reaction was stopped by addition of 100 mM EDTA and both
phosphorylated and dephosphorylated substrates were immobilized
on streptavidin-coated plate. The fraction of phosphorylated substrate
was visualized spectrophotometrically at 450 nm, using HRP-conju-
gated mouse anti-phosphotyrosine antibody (clone PY20) and an en-
suing chromogenic substrate reaction. The quantity of phosphate in-
corporated into the tyrosine kinase substrate was determined utilizing
the phosphopeptide standard curve.
2.8. Apoptosis detection
2.8.1. Annexin V-FITC test (Beckman Coulter). The exposure of
phosphatidylserine (PSer) on the cell surface was used as a criterion
for early apoptotic events. Cells (2U105/ml) were cultured as de-
scribed in Fig. 1D. After collection by centrifugation they were
washed twice with PBS, containing 2.5 mM CaCl2 (annexin V binding
bu¡er). 100 Wl of the cell suspension was incubated with 5 Wl of FITC-
conjugated annexin V (FITC-annexin V) for 10 min at RT in the
dark. The cells were washed twice with annexin binding bu¡er and
resuspended in 100 Wl of the same bu¡er. FITC-annexin V, bound to
PSer on the cell surface, was detected spectro£uorometrically at
Vem = 535 nm (Vex = 488 nm), using a Fluoromark £uorescent micro-
plate reader (Bio-Rad).
2.8.2. DNA ladder detection test (Waco). DNA fragmentation
was used as a criterion for the last phase of apoptosis. The test is
based on the fact that DNA from apoptotic cells forms a ladder on
the gel, while DNA from non-apoptotic cells appears as a single band
or smeared on the gel. Cells (2U105/ml) were cultured as described in
Fig. 1D. The lysis of cells and DNA isolation was carried out accord-
ing to the test’s protocol. DNA was analyzed by TBA electrophoresis
in a non-denaturing 6% polyacrylamide gel. Gels were stained with
SYBR Green (Sigma), according to the manufacturer’s instructions.
2.9. Cell growth arrest
Cells (2U105/ml) were cultured (in the presence or in the absence of
ODNs) as described in Fig. 1D. At each time point cell growth was
detected spectrophotometrically, using the CellTiter AQ Proliferation
Assay kit (Promega). The method is based on the detection of the
number of viable cells in proliferation. In the presence of an electron
coupling reagent (phenazine methosulfate) a tetrazolium compound
(MTS) is reduced from cells into a formazan product, based on the
method of Mosmann [16]. The absorbance of formazan product at
490 nm (OD490nm) is recorded using 96-well plate reader InterMedIm-
munomini NJ-2300 (InterMed, Japan).
2.10. Flow-FISH analysis of telomere length
Telomere length was detected by £ow cytometry using £uorescence
in situ hybridization (FISH) with FITC-labeled peptide nucleic acid
(PNA) probes. Details of the protocol are described in Baerlocher et
al. [17]. In brief, the cell pellet (5U106 for each sample) was resus-
pended and incubated for 10 min at RT in 200 Wl hybridization mix-
ture, containing 75% deionized formamide, 20 mM Tris, pH 7.1, 1%
(w/v) bovine serum albumin (BSA) and 20 mM NaCl with either no
probe (unstained control) or 0.35 Wg/ml telomere speci¢c FITC-con-
jugated (C3TA3)3 PNA probe for stained samples (Applied Biosys-
tems). DNA denaturation was carried out in a circulating water bath
for 15 min at 87‡C. The telomere PNA probe was hybridized for 90
min at RT in the dark. To remove excess and non-speci¢cally bound
telomere PNA probe, four washes were performed at RT with 1 ml
washing solution (75% formamide, 10 mM Tris, 0.1% BSA, 0.1%
Tween-20) followed by centrifugation at 1500Ug for 5 min at 16‡C.
The last wash step was performed with 1 ml washing solution, con-
taining 5% glucose, 10 mM HEPES, 0.1% BSA and 0.1% Tween-20,
and centrifugation at 900Ug for 5 min at 16‡C. After the last wash,
the cells were resuspended in a FACSFlow solution (Becton Dick-
inson), containing 0.1% (w/v) BSA, RNase A (10 Wg/ml, Boehringer)
and LDS-751 (0.01 Wg/ml, Exciton Chemicals) for at least 20 min
before acquisition on the £ow cytometer. The light scatter and £uo-
rescence signals were performed on a FACSCalibur (Becton Dickin-
son). A mixture of four populations of FITC-labeled beads (Flow
Cytometry Standards) was run for each experiment to convert £uo-
rescence into molecular equivalents of soluble £uorochrome (MESF).
Cells hybridized without the FITC-labeled telomere PNA probe were
used to correct their auto£uorescence. The telomere £uorescence was
calculated by subtraction of the auto£uorescence of unstained con-
trols from the telomere £uorescence in cells hybridized with FITC-
labeled telomere PNA probe. The mean of duplicates was calculated
for each sample. The results are expressed as telomere £uorescence in
MESF and are meansWS.E.M. from ¢ve independent experiments.
The speci¢c £uorescence of control cells (cow thymocytes) served as
an internal standard. It was used to convert the MESF values of cells
of interest into an average telomere length (in kb) by the formula
described from Baerlocher and Lansdorp [18].
2.11. Statistical analysis
One-way analysis of variance was employed, followed by Bonferro-
ni’s test for truly signi¢cant di¡erences. Statistical signi¢cance was
de¢ned as P6 0.05. The statistical procedures were performed with
GraphPad InStat software, version 2.04, USA. Data are expressed as
meanWS.D.
3. Results and discussion
The structures of chemically synthesized antisense substan-
ces are shown in Fig. 1A. They were phosphorothioate-deriv-
atized (PS-ODN1 and PS-ODN2) and non-derivatized
(ODN1 and ODN2). Two mRNA sense sequences were chos-
en. The ¢rst target for antisense ODNs was localized in the
Bcr-Abl mRNA major breakpoint, which is characterized by a
Bcr exon 3/Abl exon 2 (b3a2) junction ^ a unique sequence in
Ph(+) CML cells. The second target was localized in Bcr-Abl
mRNA, encoding the ATP binding and activation loop of the
following proteins ^ p210 Bcr-Abl and p150 c-Abl. The selec-
tion aimed to avoid the area most sensitive for point muta-
tions in the Abl part around Tyr315, responsible for Bcr-Abl
ampli¢cation and development of drug resistance (as has been
described in the clinical trials with Glivec [19^21]). In this
case, the structure of antisense ODNs can guarantee the in-
teraction with Bcr-Abl and c-Abl mRNA, despite possible
point mutations during the ‘chronic’ treatment. The structure
of PS-ODN2/ODN2 also guarantees the interaction with
c-Abl mRNA in Ph(3) Jurkat cells.
The intracellular uptake of the antisense substances was
detected by £uorescent confocal microscopy, using FITC as
a £uorescent marker (Fig. 1B,C). FITC-labeled PS-ODN1
and PS-ODN2 were detected in the cells after 24 h incubation
at 37‡C, without any transfection with lipofectamine (Fig. 1B,
green spots). Both substances were localized in the cells (in
high density sites of K-562 and very sporadically located in
Jurkat). In contrast, FITC-labeled ODN1 and ODN2 were
unable to enter K-562 and Jurkat cells up to 72 h incubation
(no £uorescent conjugates were detected in the cells, data not
shown). This is in agreement with already published observa-
tions demonstrating that free ODNs do not penetrate or
hardly penetrate cell membranes in the absence of a speci¢c
carrier [22^24]. However, after transfection using lipofectam-
ine, both antisense substances were detected in the cells after
24 h incubation. Analogous to PS-ODN1/PS-ODN2, the lo-
calization of ODN1/ODN2 was most sporadic in Jurkat, and
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was predominantly into the high density sites of K-562 cells.
To guarantee equal experimental conditions and ODN cell
concentrations, as well as enough time for re-synthesis of tar-
get proteins, transient transfection with lipofectamine was ap-
plied for each antisense substance and the cells were treated
‘chronically’ as shown in Fig. 1D. The selection of the ODN/
lipofectamine ratio aimed to avoid the side e¡ects of lipofect-
amine on cell viability and proliferation. The ‘chronic’ treat-
ment of cells with antisense substances minimizes their elimi-
nation as a result of nuclease degradation [25]. This treatment
guarantees most stable steady-state concentrations of the anti-
sense substances in the cells in comparison with single dose
application. It allows the expression of e¡ects as a result of a
‘long-term’ treatment. In preliminary experiments we estab-
lished that 5 WM ODNs (single dose) decreased the level of
p210 Bcr-Abl and the e¡ect was better expressed at 48 h post
transfection than after 24 and 72 h. Moreover, the treatment
of cells with single dose ODNs did not signi¢cantly reduce the
level of p210 Bcr-Abl at 72 h post transfection (data not
shown). Similar e¡ects have also been reported for Bcr-Abl
antisense peptide nucleic acids [23]. Based on these observa-
tions, treatment with antisense ODNs every 2 days was ap-
plied. Cells treated with lipofectamine only were used as con-
trols. Statistically signi¢cant e¡ects of lipofectamine on the
parameters analyzed were not detected. Control groups also
included the data obtained for cells transfected with nonsense
or sense ODNs/PS-ODNs (except in the case of cell growth
arrest and tankyrase analyses), because the results were anal-
Fig. 3. A: E¡ect of anti-Bcr-Abl/c-Abl mRNA ODNs (6 days treatment) on the induction of apoptosis in Ph(+) K-562 and Ph(3) Jurkat cells.
A1: Annexin V-FITC test for detection of apoptosis (Beckman Coulter). Cells were cultured during 6 days as described in Fig. 1D and col-
lected by centrifugation. They were washed twice with PBS and resuspended in annexin binding bu¡er (2U105 cells/ml). The cell suspension
was incubated with FITC-conjugated annexin V as described in Section 2. FITC-annexin V, bound to PSer on the cell surface, was detected
spectro£uorometrically at Vex = 488 nm and Vem = 535 nm. The data are presented as meansWS.D. from six independent experiments. Control
groups are representative for non-treated cells, cells treated with lipofectamine only, and for cells transfected with sense or nonsense ODNs/PS-
ODNs. A2: DNA ladder detection test (Waco). The test is based on the fact that DNA from apoptotic cells forms a ladder on the gel, while
DNA from non-apoptotic cells appears as a single band or smeared on the gel. Cells were cultured during 6 days as described in Fig. 1D and
collected by centrifugation. Cell lysis and DNA isolation were carried out according to the test’s protocol. DNA was analyzed by TBA electro-
phoresis in 6% polyacrylamide gel. Gels were stained with SYBR Green. St, standard marker (stable 100 bp DNA ladder, Sigma). Four inde-
pendent experiments were carried out. Blots from one typical experiment are shown in the ¢gure. Note that no DNA fragmentation was de-
tected in antisense-treated leukemic cells. Control blots are representative for cells treated with lipofectamine only, and for cells transfected
with sense or nonsense ODNs/PS-ODNs. B: E¡ect of anti-Bcr-Abl/c-Abl mRNA ODNs on the amount of viable cells. Cells were cultured in
the presence or in the absence of antisense ODNs as described in Fig. 1D. At each time point the amount of viable cells in proliferation was
detected spectrophotometrically, based on the reduction of MTS into a formazan product (absorbance at 490 nm). The data were calculated as
T/C, where T is OD490nm of ODN-treated cells, and C is OD490nm of non-treated cells. They are presented as mean values from nine indepen-
dent experiments. S.D. values did not exceed 10% of the respective mean value. In the case of K-562, the control group included cells treated
with lipofectamine only and cells treated with sense or nonsense ODNs. In the case of Jurkat, the control group included cells treated with
lipofectamine only, and cells treated with sense or nonsense ODNs/PS-ODNs.
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ogous to those obtained for non-treated cells and cells treated
with lipofectamine only. All control data were pooled together
in common control groups.
The capacity of antisense ODNs to reduce the expression of
Bcr-Abl and c-Abl in K-562 and Jurkat cells, respectively, was
measured by immunoblot analysis and £ow cytometry (Fig.
2A,B), using anti-c-Abl antibody with known speci¢city to
150 kDa c-Abl- and 210 kDa Bcr-Abl-encoded proteins (Sig-
ma). Fig. 2A shows typical Western blots on days 2, 4 and 6
of treatment. The treatment of K-562 cells with PS-ODN1/PS-
ODN2 or ODN1/ODN2 markedly reduced the level of p210
Bcr-Abl protein compared to that in non-treated cells even on
day 2, and the e¡ect was relatively stable on day 6 (Fig. 2A).
Similar results were obtained by £ow cytometric registration
of the level of Bcr-Abl^antibody complexes, using Fluor-488
IgG-labeled anti-c-Abl antibody (ZenonAlexa) (Fig. 2B).
These e¡ects were accompanied by about 60^80% decrease
of PTK activity of the immunoprecipitated enzyme and about
45^60% decrease of PTK activity, determined in cell lysates on
day 6 (Fig. 2C,D). The e¡ects of PS-ODNs on the level of
Bcr-Abl protein and its enzyme activity were better expressed
than those of the non-derivatized ODNs. Probably it is a
result of the higher stability of PS-ODNs in physiological
£uids and cell suspensions in comparison with ODNs [25].
Four days treatment of Jurkat cells with PS-ODN1 or
ODN1 did not a¡ect c-Abl protein level, nor its enzyme ac-
tivity (Fig. 2). This is not surprising since Bcr-Abl fusion
protein mRNA does not exist in Jurkat cells and therefore,
there is no target for PS-ODN1 and ODN1. These data in-
dicate also that PS derivatization does not provoke non-spe-
ci¢c side e¡ects of ODN substances in the concentrations
applied. However, the treatment of Jurkat with PS-ODN2
(targeted to Abl mRNA encoding the ATP binding loop)
resulted in a decrease of p150 c-Abl protein and the e¡ect
was markedly expressed on days 4 and 6 (Fig. 2A,B). It was
accompanied by an about 40^60% decrease of PTK activity of
Jurkat cells on day 6 (Fig. 2C,D).
The e¡ects of antisense substances on Bcr-Abl/c-Abl were
not a result of cytotoxicity and induction of apoptosis. ODNs
did not manifest signi¢cant cytotoxic e¡ects against K-562
and Jurkat, determined by the cellular ATP bioluminescence
(data not shown). They did not induce apoptosis, estimated
by PSer exposure on the cell surface or by DNA fragmenta-
tion (Fig. 3A1,A2). However, all substances signi¢cantly de-
creased the cell growth of K-562 and did not provoke cell
growth arrest in Jurkat (Fig. 3B). Moreover, the treatment
with PS-ODN2 signi¢cantly increased the number of viable
Jurkat cells on days 4 and 6. PS-derivatized sense and non-
sense ODNs manifested poor antiproliferating activity after
6 days treatment of K-562 cells, probably as a result of a
non-speci¢c e¡ect of phosphorothioate on this parameter.
To clarify whether the changes in Bcr-Abl/c-Abl origin in-
£uence telomerase, the telomerase activity was evaluated at
each time point of the cell treatment, using a conventional
TRAP and Stretch PCR [14]. Fig. 4A shows that during
2 days treatment the telomerase activity decreased slightly in
K-562 cells (V10^15%), this e¡ect disappeared on day 4 and
reverted to a signi¢cant increase of telomerase activity
(V30%) on day 6. Although the viability and proliferating
activity of K-562 cells are very sensitive to the amount of
Bcr-Abl fusion protein (cell growth arrest was shown in Fig.
3B), it seems that the cells keep a potential to restore prolif-
eration and immortalization through telomerase activation.
The alteration of the telomerase activity of K-562 was not
accompanied by variations in its catalytic subunit. The
hTERT level was constant during 6 days treatment. No var-
iations were detected either in phospho-Tyr-hTERT (Fig. 3B,
6 days treatment). This puts into doubt the hypothesis that
the increased telomerase activity in ODN-treated K-562 cells
is a result of decreased Tyr phosphorylation of telomerase by
Bcr-Abl. Presumably, in native cells the cross-talk between
both enzymes was not mainly mediated through the Tyr phos-
phorylation/dephosphorylation pathway and the link between
both enzymes is indirect.
In the last 3^4 years it has been established that the telo-
merase-mediated telomere elongation in cancer cells is tightly
regulated not only by hTERT status and integrity of the te-
lomerase molecule, but also by several telomeric-associated
proteins (TRF1, TRF2, Tin2, tankyrase, Rap1) that regulate
the access of telomerase to the telomeres [26^31]. The accent
in our work was on TRF1 (telomeric repeat binding factor, a
56 kDa protein) and Tin2 (V40 kDa protein), which have
C
Fig. 4. A: Telomerase activity assay in Ph(+) K-562 and Ph(3) Jurkat cells, treated with antisense Bcr-Abl/c-Abl mRNA ODNs. Telomerase
activity was detected by conventional TRAP and Stretch PCR. Nine independent assays for each sample were performed. The concentration of
TRAP products was detected spectrophotometrically at V=450 nm, and the results were calculated as a percentage of the subsequent positive
control (C1, C2). The mean absorbance of controls at 450 nm for all time points was 1.846W0.205 for Jurkat and 1.057W 0.083 for K-562. The
absorbance of negative controls at 450 nm was 0.155W0.028 and this value was subtracted from each result. *P6 0.05 vs. control group,
**P6 0.01 vs. control group, ***P6 0.001 vs. control group. Blots from one typical experiment after 6 days treatment are also shown in the
¢gure. Positive controls are representative for cell lysates, obtained from antisense non-treated cells, cells treated with lipofectamine only, and
for cells transfected with sense or nonsense ODNs/PS-ODNs. Negative controls are representative for cell lysates (obtained from treated or
non-treated cells), subjected to 70‡C for 10 min, before initiating of telomerase reaction. B: Levels of hTERT, TRF1, Tin2 and tankyrase in
Ph(+) K-562 and Ph(3) Jurkat cells, treated with antisense Bcr-Abl/c-Abl mRNA ODNs ^ Western blot analysis. Cells were lysed by Telo-
Chaser bu¡er (for hTERT analysis) or by TNE bu¡er (for TRF1, Tin2 or tankyrase analysis). Cell lysates were suspended 1:1 (v/v) in
2ULaemmli bu¡er and the samples were fractionated by 5% stacking, 8% resolving (for hTERT) or 4^20% resolving SDS^polyacrylamide gel
(for TRF1, Tin2 and tankyrase). Proteins were immunoblotted as described in Section 2. The following primary antibodies were used: anti-
hTERT (rabbit, Calbiochem, 0.4 Wg/ml), anti-tankyrase (rabbit, Calbiochem, 0.1 Wg/ml), anti-TRF1 (rabbit, Calbiochem, 0.7 Wg/ml), anti-Tin2
(mouse, Calbiochem, 0.5 Wg/ml), anti-L-actin (mouse, Sigma, 0.1 Wg/ml). The respective secondary antibodies (goat anti-rabbit or anti-mouse
IgG), conjugated with HRP, were applied. Chemiluminescence of the blots was detected immediately using ECL Advance Western Blotting De-
tection kit. Seven independent experiments for hTERT and six for tankyrase, TRF1 and Tin2 were carried out. Blots from one typical experi-
ment for each protein are shown in the ¢gure. The histograms show T/C, where T is the chemiluminescence of the blots obtained from anti-
sense-treated cells, and C is the chemiluminescence of the blots obtained from control untreated cells. In the case of hTERT, TRF1 and Tin2,
control blots are representative for antisense non-treated cells, cells treated with lipofectamine only, and for cells transfected with sense or non-
sense ODNs/PS-ODNs. In the case of tankyrase in Jurkat, control blots are representative for antisense non-treated cells, cells treated with
lipofectamine only, and for cells transfected with sense ODN3/PS-ODN3 or nonsense ODN5/PS-ODN5.
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been identi¢ed as negative regulators of the telomerase func-
tion, and on tankyrase (a 142 kDa protein, poly-(ADP-ri-
bose)-polymerase), which has been accepted as a positive reg-
ulator [27^30]. The interaction between these three factors
seems to be simple and strongly organized to control the
access of telomeric TTAGGG repeats to telomerase. Tin2/
TRF1 has been found to interact with telomeric DNA and
to remodel DNA con¢guration. This suppresses the access of
telomeric repeats for telomerase. Tankyrase has been identi-
¢ed as a TRF1-interacting factor [30]. Tankyrase-mediated
poly-(ADP-ribosyl)ation of TRF1 induces the release of
TRF1 from telomeres, opening up the telomeric complex
and allowing the access to telomerase [30,31]. All these factors
did not directly modulate the telomerase.
To evaluate whether the decreased amount of Bcr-Abl af-
fects this mechanism of telomere length control, we deter-
mined the levels of TRF1, Tin2 and tankyrase in ODN-
treated and non-treated cells, using adequate antibodies
(anti-TRF1, anti-Tin2 and anti-tankyrase) and immunoblot
analysis. Because the endogenous TRF1 and Tin2 are usually
not highly expressed in CML, several modi¢cations of the
standard Western blot procedures were made to identify
both substances in non-treated and treated K-562 cells
[27,28]. The results in Fig. 4B show that the amounts of
TRF1 and Tin2 decreased markedly in ODN-treated K-562
cells on days 4 and 6, while the amount of tankyrase increased
slightly on day 4, and signi¢cantly on day 6. The results sug-
gest that the anti-Bcr-Abl mRNA-treated K-562 cells keep a
potential for indirect induction of telomerase activity through
overexpression of tankyrase and decreased expression of Tin2/
TRF1. These variations in telomeric-associated proteins can
provoke most free access of telomeres for the telomerase and
positive telomerase control, as well as enhancing the possibil-
ity for ‘alternative telomere lengthening’. We established also
that the growth arrest of K-562 goes to a plateau during
6 days treatment with anti-Bcr-Abl ODNs (Fig. 3B). How-
ever, no telomere elongation was observed during 6 days
treatment, detected by £ow-FISH analysis (Fig. 5). Telomere
length was relatively stable during treatment ^ indirect evi-
dence that the cells keep their proliferation capacity.
Recently Brummendorf and colleagues have reported an
extension of the telomeres in CML patients after long-term
treatment with the Bcr-Abl tyrosine kinase inhibitor Glivec
[32] in both chronic phase and blast crisis. Analyzing 517
samples from 206 patients the authors established that telo-
mere length from the start of treatment up to day 144 is
signi¢cantly shorter compared to patients treated for more
than 144 days. In patients with repeated measurements, a
signi¢cant increase in telomere length under treatment is ob-
served. Median telomere length in major remission has been
found to be signi¢cantly longer in comparison to patients
without response to treatment, measured either by cytoge-
netics, interphase FISH, or quantitative reverse transcription
PCR. However, the authors did not investigate the mechanism
of telomere elongation and the e¡ect of Glivec on the factors
potentially responsible for this process.
Obviously, there is a possibility for telomere elongation
after long-term treatment of Ph(+) cells with Bcr-Abl inhib-
itors. To verify this assumption we used the following exper-
imental protocol: K-562 cells were treated during 36 days
with PS-ODN2 on the scheme shown in Fig. 1D. However,
to avoid the side e¡ects of lipofectamine during many trans-
fection procedures, we applied PS-ODN2 every 2 days in a
single dose of 5 WM without any transfection. The results in
Fig. 6 demonstrate that the long-term treatment of K-562
with PS-ODN2 induced a signi¢cant telomere elongation, ac-
companied by overexpression of tankyrase and increased te-
lomerase activity. Moreover, overexpression of hTERT was
also detected, which was not observed during short-term
treatment (6 days). This may give rise to speculation that
Bcr-Abl is responsible for regulation of hTERT expression
and/or its synthesis and the long-term treatment with anti-
Bcr-Abl substances makes it possible to detect the relationship
between both oncogenes/oncoproteins. Obviously, a cross-talk
exists between them and it is necessary to verify whether it is
direct or mediated by other factors, which will be our future
e¡ort. It seems that the cells treated with anti-Bcr-Abl mRNA
substances are adapted to the decreased amount of Bcr-Abl
protein and trigger some other compensatory mechanism for
preservation of the proliferation as telomerase activation.
Fig. 5. Flow-FISH telomere £uorescence performed in K-562 and
Jurkat cells, treated with antisense Bcr-Abl/c-Abl mRNA ODNs.
The £ow cytometry-based method using FISH with FITC-labeled
PNA probe was applied for detection of telomere length in the cells
before and after 6 days treatment with antisense Bcr-Abl/c-Abl
mRNA ODNs. Cells hybridized without FITC-labeled telomere
PNA probe were used to correct their auto£uorescence. The telo-
mere £uorescence of cells was calculated by subtraction of the auto-
£uorescence of unstained controls from the telomere £uorescence
measured in cells hybridized with the FITC-labeled telomere PNA
probe. The results are expressed as telomere £uorescence in MESF
and are the meansWS.E.M. from ¢ve independent experiments. The
control group included non-treated cells and cells treated with lipo-
fectamine only. *P6 0.05 vs. control group.
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The relationship between Abl tyrosine kinase and telomer-
ase was con¢rmed also from the results on Jurkat cells. It was
established that the telomerase activity increased on day 6 in
anti-c-Abl mRNA-treated Jurkat cells (ODN2, PS-ODN2).
This e¡ect was accompanied by a decrease in TRF1 and
Tin2 on days 4^6, a signi¢cant increase of tankyrase even
on day 4 (in PS-ODN2-treated cells), enhancement of the
number of viable cells in proliferation (Figs. 3B and 4) and
telomere elongation during 6 days treatment with PS-ODN2
(Fig. 5). Converting MESF values into kilobases by the equa-
tion described by Baerlocher and Lansdorp [18], it was estab-
lished that in Jurkat cells the mean telomere length increased
from 4.356 kb in control cells to 5.139 kb even after 6 days
treatment with PS-ODN2 (P6 0.05).
In conclusion, the present study provides evidence that
cross-talk exists between Bcr-Abl/c-Abl tyrosine kinase and
Fig. 6. A: Levels of Bcr-Abl, hTERT, and tankyrase in K-562 after long-term treatment with PS-ODN2 (36 days) ^ Western blot analysis.
Cells were lysed by TeloChaser bu¡er (for hTERT analysis) or by TNE bu¡er (for tankyrase analysis). Cell lysates were suspended 1:1 (v/v) in
2ULaemmli bu¡er and the samples were fractionated by 5% stacking, 8% resolving (for hTERT) or 4^20% resolving SDS^polyacrylamide gel
(for tankyrase). Proteins were immunoblotted as described in Section 2. The following primary antibodies were used: anti-hTERT (rabbit, Cal-
biochem, 0.4 Wg/ml), anti-tankyrase (rabbit, Calbiochem, 0.1 Wg/ml), anti-L-actin (mouse, Sigma, 0.1 Wg/ml). The respective secondary antibodies
(goat anti-rabbit or anti-mouse IgG), conjugated with HRP, were applied. Chemiluminescence of the blots was detected immediately using
ECL Advance Western Blotting Detection kit. Six independent experiments for each protein were carried out. Blots from one typical experi-
ment for each protein are shown in the ¢gure. Control blots are representative for non-treated cells. B: Telomerase activity assay in K-562 after
long-term treatment with PS-ODN2 (36 days). Telomerase activity was detected by conventional TRAP and Stretch PCR. Six independent as-
says for each sample were performed. The concentration of TRAP products was detected spectrophotometrically at V=450 nm. The absorbance
of negative controls at 450 nm was subtracted from each result. *P6 0.05 vs. control group. Blots from one typical experiment are also shown
in the ¢gure. Controls are representative for cell lysates, obtained from non-treated cells. C: Flow-FISH telomere £uorescence performed in
K-562 after long-term treatment with PS-ODN2 (36 days). The £ow cytometry-based method using FISH with FITC-labeled PNA probe was
applied for detection of telomere length in the cells before and after 36 days treatment with antisense PS-ODN2, sense PS-ODN4 or nonsense
PS-ODN5. Cells hybridized without FITC-labeled telomere PNA probe were used to correct their auto£uorescence. The telomere £uorescence
of cells was calculated by subtraction of the auto£uorescence of unstained controls from the telomere £uorescence measured in cells hybridized
with the FITC-labeled telomere PNA probe. The results are expressed as telomere £uorescence in MESF and are the meansWS.E.M. from six
independent experiments. Control group included non-treated cells. *P6 0.05 vs. control group.
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telomerase in CML/ALL cells respectively, and the relatively
long-term inhibition of the synthesis of Bcr-Abl/c-Abl proteins
keeps a potential for restoration of cell proliferation through
telomerase activation and/or overexpression of tankyrase.
These observations provoke a question: does this mechanism
take place in the development of resistance to the highly se-
lective Bcr-Abl drugs, applied in CML therapy? It seems that
two independent e¡ects can be accumulated after long-term
treatment with anti-Bcr-Abl substances ^ reactivation of Bcr-
Abl ampli¢cation as a result of point mutations in the Abl
kinase domain [19^21], and/or continued suppression of Bcr-
Abl synthesis, accompanied by an induction of alternative
telomerase-dependent signaling pathways. Both mechanisms
lead to restoration of abnormal proliferation of leukemia
cells. In this context, the combined application of anti-Bcr-
Abl drugs and substances in£uencing telomere lengthening
may be a promising strategy in CML control. Recently pub-
lished data, demonstrating that the inhibition of human telo-
merase enhances the e¡ect of the tyrosine kinase inhibitor
Glivec in Ph(+) cells, support this assumption [33].
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